Licensing status

Publication and contact information


Gene expression signature as a prostate cancer prognostic

A 32-gene expression signature could help guide the choice of postoperative treatment for prostate cancer. Bioinformatic analysis of the expression of 1,536 genes in malignant prostate tissue isolated from patients with prostate cancer following radical prostatectomy identified a 32-gene expression signature that correlated with outcome. The signature was validated in a blinded cohort of 270 patients, in which it had greater prognostic value than existing clinical markers. Next steps include looking prospectively to test whether the expression signature predicts disease progression.
The work was carried out in collaboration with the bioTheranostics Inc. subsidiary of bioMerieux S.A.

SciBX 6(18); doi:10.1038/scibx.2013.452
Published online May 9, 2013

Patented; unavailable for licensing

Wu, C.-L. et al. Proc. Natl. Acad. Sci. USA; published online March 26, 2013;
Contact: W. Scott McDougal, Massachusetts General Hospital, Boston, Mass.